1.15
1.15 (0%)
As of Apr 28, 2025
Anebulo Pharmaceuticals, Inc. [ANEB]
Source:
Company Overview
Anebulo Pharmaceuticals, Inc is a clinical-stage biotechnology company developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (“ACI”) and the broader landscape of acute cannabis-induced conditions.
| Country | United States |
| Headquarters | lakeway, texas |
| Phone Number | 737 203 5270 |
| Industry | manufacturing |
| CEO | Richard Anthony Cunningham |
| Website | www.anebulo.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-2.6 |
| Net Income | $-2.5 |
| Net Cash | $11.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -24.7% |
| Profit as % of Stockholder Equity | -16.5% |
Management Effectiveness
| Return on Equity | -16.5% |
| Return on Assets | -15.6% |
| Turnover Ratio | |
| EBITA | $-2.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $15.8 |
| Total Liabilities | $0.9 |
| Operating Cash Flow | $-3.1 |
| Investing Cash Flow | |
| Financing Cash Flow | $15 |
